FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756139631> ?p ?o ?g. }

• W2756139631 endingPage "2668" @default.
• W2756139631 startingPage "2663" @default.
• W2756139631 abstract "Background: Cabazitaxel is a second-generation taxane that is approved for use with concomitant low dose daily prednisone in metastatic castration resistant prostate cancer (mCRPC) after docetaxel failure. Since the role of daily corticosteroids in improving cabazitaxel efficacy or ameliorating its safety profile has not been adequately investigated so far, we compared outcomes of patients receiving cabazitaxel with or without daily corticosteroids in a retrospective single-Institution cohort of mCRPC patients. Patients and methods: Medical records of deceased patients with documented mCRPC treated with cabazitaxel following prior docetaxel between January, 2011 and January, 2017 were reviewed at the single participating center. Patients who were receiving daily doses of systemic corticosteroids other than low dose daily prednisone or prednisolone (<= 10 mg a day) were excluded. The primary end point of this analysis was overall survival (OS). Secondary end-points were exposure to cabazitaxel as well as incidence of grade 3-4 adverse events. Univariable and multivariable Cox proportional hazards regression was used to evaluate prednisone use and other variables as potentially prognostic for overall survival. Results: Overall, among 91 patients, 57 patients received cabazitaxel concurrently with low dose prednisone and 34 patients did not receive concurrent prednisone. The median overall survival of the population was 9.8 months (interquartile range, 9 to 14). Patients receiving prednisone had an overall survival of 9 months (interquartile range, 8 to 12) vs.14 months (interquartile range, 9.4 to 16.7) for patients not treated with prednisone. Approximately 45% of patients had a >30% PSA decline at 12 weeks. Prednisone use was not significantly prognostic for overall survival or PSA decline ≥30% rates on regression analyses. Importantly, a >30% PSA decline at 12, but not at 3, 6, 9 weeks, was prognostic for improved survival at multivariate analysis Conclusions: The data presented here support the hypothesis that omitting daily corticosteroids in cabazitaxel-treated patients has no negative impact on either survival or safety profile. In the large prospective trial CABACARE, cabazitaxel-treated patients will be randomized to receive or not receive daily prednisone. The CABACARE (EudraCT n. 2016-003646-81) study is currently ongoing at University Federico II of Naples and at other multiple participating centers in Italy." @default.
• W2756139631 created "2017-09-25" @default.
• W2756139631 creator A5002293697 @default.
• W2756139631 creator A5004302913 @default.
• W2756139631 creator A5010144168 @default.
• W2756139631 creator A5016450267 @default.
• W2756139631 creator A5019284296 @default.
• W2756139631 creator A5021770361 @default.
• W2756139631 creator A5022468686 @default.
• W2756139631 creator A5039561552 @default.
• W2756139631 creator A5045479314 @default.
• W2756139631 creator A5048529499 @default.
• W2756139631 creator A5051163510 @default.
• W2756139631 creator A5052069729 @default.
• W2756139631 creator A5053348898 @default.
• W2756139631 creator A5060962611 @default.
• W2756139631 creator A5064453022 @default.
• W2756139631 creator A5064799831 @default.
• W2756139631 creator A5068552086 @default.
• W2756139631 creator A5078562748 @default.
• W2756139631 creator A5080471419 @default.
• W2756139631 creator A5085376563 @default.
• W2756139631 creator A5091232717 @default.
• W2756139631 date "2017-01-01" @default.
• W2756139631 modified "2023-10-05" @default.
• W2756139631 title "The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer" @default.
• W2756139631 cites W1797512951 @default.
• W2756139631 cites W1858638128 @default.
• W2756139631 cites W1893347245 @default.
• W2756139631 cites W1991233593 @default.
• W2756139631 cites W2000530779 @default.
• W2756139631 cites W2004973733 @default.
• W2756139631 cites W2064016579 @default.
• W2756139631 cites W2078559150 @default.
• W2756139631 cites W2085286861 @default.
• W2756139631 cites W2093924402 @default.
• W2756139631 cites W2110534364 @default.
• W2756139631 cites W2123526148 @default.
• W2756139631 cites W2137467802 @default.
• W2756139631 cites W2151241358 @default.
• W2756139631 cites W2168011358 @default.
• W2756139631 cites W2169702768 @default.
• W2756139631 cites W2245153926 @default.
• W2756139631 cites W2303177091 @default.
• W2756139631 cites W2315433944 @default.
• W2756139631 cites W2519193025 @default.
• W2756139631 cites W2523960744 @default.
• W2756139631 cites W2527612886 @default.
• W2756139631 cites W2568045406 @default.
• W2756139631 cites W2917837889 @default.
• W2756139631 doi "https://doi.org/10.7150/jca.20040" @default.
• W2756139631 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5604196" @default.
• W2756139631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28928853" @default.
• W2756139631 hasPublicationYear "2017" @default.
• W2756139631 type Work @default.
• W2756139631 sameAs 2756139631 @default.
• W2756139631 citedByCount "5" @default.
• W2756139631 countsByYear W27561396312018 @default.
• W2756139631 countsByYear W27561396312019 @default.
• W2756139631 countsByYear W27561396312020 @default.
• W2756139631 countsByYear W27561396312021 @default.
• W2756139631 countsByYear W27561396312023 @default.
• W2756139631 crossrefType "journal-article" @default.
• W2756139631 hasAuthorship W2756139631A5002293697 @default.
• W2756139631 hasAuthorship W2756139631A5004302913 @default.
• W2756139631 hasAuthorship W2756139631A5010144168 @default.
• W2756139631 hasAuthorship W2756139631A5016450267 @default.
• W2756139631 hasAuthorship W2756139631A5019284296 @default.
• W2756139631 hasAuthorship W2756139631A5021770361 @default.
• W2756139631 hasAuthorship W2756139631A5022468686 @default.
• W2756139631 hasAuthorship W2756139631A5039561552 @default.
• W2756139631 hasAuthorship W2756139631A5045479314 @default.
• W2756139631 hasAuthorship W2756139631A5048529499 @default.
• W2756139631 hasAuthorship W2756139631A5051163510 @default.
• W2756139631 hasAuthorship W2756139631A5052069729 @default.
• W2756139631 hasAuthorship W2756139631A5053348898 @default.
• W2756139631 hasAuthorship W2756139631A5060962611 @default.
• W2756139631 hasAuthorship W2756139631A5064453022 @default.
• W2756139631 hasAuthorship W2756139631A5064799831 @default.
• W2756139631 hasAuthorship W2756139631A5068552086 @default.
• W2756139631 hasAuthorship W2756139631A5078562748 @default.
• W2756139631 hasAuthorship W2756139631A5080471419 @default.
• W2756139631 hasAuthorship W2756139631A5085376563 @default.
• W2756139631 hasAuthorship W2756139631A5091232717 @default.
• W2756139631 hasBestOaLocation W27561396311 @default.
• W2756139631 hasConcept C119060515 @default.
• W2756139631 hasConcept C121608353 @default.
• W2756139631 hasConcept C126322002 @default.
• W2756139631 hasConcept C141071460 @default.
• W2756139631 hasConcept C143998085 @default.
• W2756139631 hasConcept C168563851 @default.
• W2756139631 hasConcept C197934379 @default.
• W2756139631 hasConcept C203092338 @default.
• W2756139631 hasConcept C207103383 @default.
• W2756139631 hasConcept C2777899217 @default.
• W2756139631 hasConcept C2778720950 @default.
• W2756139631 hasConcept C2778971682 @default.
• W2756139631 hasConcept C2780192828 @default.

• next